Podcasts about gynecology

Today, we are tackling a massive grey area in obstetrics/maternal-fetal medicine: What happens after early fetal growth restriction resolves? When a baby bounces back on the growth chart during the second or third trimester, are they completely out of the woods? Or is there a hidden, lingering risk we aren't talking about enough? To find out, we're doing a deep dive into two major publications that dropped just this month, in August 2026 in sister journals (AJOG and AJOG MFM). Both are retrospective, both ask the exact same burning question…and get this: they arrive at completely opposing conclusions. How is that possible? Listen in for details. 1. Melamed B, Mei-Dan E, Aviram A. Sonographic fetal weight estimation percentiles should be interpreted with caution in the second trimester. Int J Gynaecol Obstet. 2026 May;173(2):930-939. doi: 10.1002/ijgo.70693. Epub 2025 Nov 25. PMID: 41288086.2. Ramos SZ, Has P, Gimovsky AC, Danilack VA, Savitz DA, Lewkowitz AK. Outcomes among Neonates after a Diagnosis of Persistent or Transient Fetal Growth Restriction Delivered at Term. Am J Perinatol. 2024 May;41(S 01):e1470-e1477. doi: 10.1055/a-2051-3859. Epub 2023 Mar 9. Erratum in: Am J Perinatol. 2024 May;41(S 01):e1478. doi: 10.1055/s-0044-1786526. PMID: 36894159; PMCID: PMC10562520.3. Keller N, Jackson F, Abelman S .Neonatal morbidity following resolution of fetal growth restriction diagnosed at second-trimester anatomy ultrasound. American Journal of Obstetrics & Gynecology MFM, 2026; Aug 8. 4. Cenac LA, Wodoslawsky S, Patel V, McLaren Jr. R, Aghai ZH, Makhamreh MM, Al-Kouatly HB, Persistent, Resolved, and Absent Fetal Growth Restriction: A Comparison of Neonatal Outcomes, American Journal of Obstetrics and Gynecology (2026), doi: https:// doi.org/10.1016/j.ajog.2026. Aug 19

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Endometrial cancer cases are rising — and abnormal bleeding is the warning sign women should never ignore. Who is most at risk, why are more women being diagnosed, and what symptoms should prompt a call to your doctor?In this episode of Baptist Health Talk, host Sandra Peebles speaks with Dr. John Diaz, gynecological oncologist at the Herbert Wertheim Cancer Institute, about what women need to know about endometrial cancer, from early warning signs and risk factors to diagnosis, treatment and fertility-preserving options. Why endometrial cancer cases are increasing in the U.S. and around the world  How obesity and prolonged estrogen exposure can raise risk  The abnormal bleeding patterns women should report — including after menopause  Other warning signs such as pelvic pain, bloating and abnormal discharge  Why endometrial cancer can also affect younger women  How doctors diagnose endometrial cancer and why there is no routine screening test  Treatment options for early and advanced disease, including immunotherapy  When fertility-sparing treatment may be possible  How family history and Lynch syndrome can affect riskHost:Sandra PeeblesAward-Winning JournalistGuest:John P. Diaz, M.D.Chief of Gynecologic OncologyHerbert Wertheim Cancer InstituteChair, Obstetrics & Gynecology, FIUIf you found this episode helpful, we also recommend the following:Can Cervical Cancer Be Cured? A Gynecologic Oncologist AnswersEradicating Cervical Cancer: Possible or Impractical?

Recent research shows that between 40 and 60% of women either change or quit their sport due to bladder leaks. That's 100% too many in our book. So this week we sat down with Dr. Lauren Siff, a double board-certified urogynecologist to demystify one of women's health's most under-discussed issues: urinary leakage. We break down the differences between stress and urge incontinence, why athletes and active women are prone to leaking, and how the menopausal transition can worsen the situation through declining estrogen, shifting vaginal pH, and rising UTI risk. Dr. Siff walks us through the full range of solutions, from pelvic floor exercises and support devices to Botox, bladder stimulators, and the game-changing role of vaginal estrogen, plus how to know when it's time to seek care. Her message is loud and clear in this one: no matter how small or severe the symptoms, there's help available — and you never have to stop doing what you love.Dr. Siff is a double board-certified urogynecologist and Chief of Gynecology and Urogynecology for the Central Virginia VA Health Care System and Associate Professor at VCU School of Medicine and VCU Institute of Engineering. A dedicated innovator and surgical educator — with a Distinguished Educator certificate from the Cleveland Clinic and founder of SurgicalEd VR, which uses VR and haptic technology to improve the quality, safety, cost-effectiveness, and accessibility of surgical training. She also serves board and committee roles with the Society for Gynecologic Surgeons, American Urogynecologic Society, and American Association of GYN Laparoscopists. She is Central Virginia Site Lead for the National VA Women's Health Research Network, and chairman of the U.S. National Surgery Office's Surgical Advisory Board for GYN. Philanthropically, she directs surgeon training for Global Surgical Expedition, driven by a mission to democratize access to surgical training and vital surgical procedures worldwide.FeistyFit Info: https://livefeisty.com/training/running/feistyfitfall/Join us at Feisty Fest September 18-20, 2026: https://livefeisty.com/events/feisty-fest/Women's Mechanic Camp in Tucson: https://livefeisty.com/events/bike-mechanic-school-tucson/Courses and Coaching: https://livefeisty.com/courses/Sign up for our FREE Feisty 40+ newsletter: https://livefeisty.com/newsletters/feisty-40/Follow Us on Instagram:Feisty Menopause: @feistymenopauseHit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099Support our Partners:Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/Previnex: Get 15% off your order with code HITPLAY at https://www.previnex.com/ Wahoo: Use the code FEISTY2026 to get a free Headwind Smart Fan (value $300) with the purchase of a Wahoo KICKR RUN at https://shorturl.at/WVhdr

Today, we are taking a deep dive into a medical truth thatsounds completely counterintuitive, almost upside down, based on everything you think you know about women's health. But here's the kicker: it's actually nothing new at all. For over two decades, ever since the landmark Women'sHealth Initiative (WHI) study made global headlines back in 2002, the blanket narrative surrounding menopausal hormone therapy has been clear and persistent: hormones equal breast cancer risk. But there is a massive asterisk in thatscience that got completely lost in the media noise. While combination therapy with conjugated equine estrogens paired with medroxyprogesterone acetate (CEE +MPA) did show an increased risk, the story for estrogen-only therapy (mainly CEE) in women wh had a hysterectomy is entirely different. In fact, an overwhelming mountain of growing data shows that estrogen-only therapy is protectiveagainst both breast cancer incidence and breast cancer mortality. In this episode, we're unpacking the latest high-level evidence that cements this crucial distinction. We'll examine the broad statistical landscape, including a comprehensive meta-analysis by Qing et al. (officially set for the December 2026 issue of Annals of Medicine, following its ahead-of-print release in March 2026). Their work breaks down how randomized controlled trial data consistentlypoint to estrogen-only therapy having a protective effect, in stark contrast to combination therapy. We'll also dive into a brand-new Clinical Perspective published in mid-August 2026 in Obstetrics & Gynecology (the Green Journal) by Drs. Andrew Kaunitz and Jason Wright. They call urgent attention to this phenomenon, highlighting RCT meta-analyses that demonstrate a 23% reduction in breast cancer incidence with estrogen alone (RR = 0.77), alongside striking cohort data showing a dramatic risk reduction even in high-risk populations, like carriers of the BRCA mutation.  Listenin for details.1.     Wu Q, Shen L, Hu S, Yang R, Wang Y, Xue D, SunY, Ma H, Dai Z. Relationship between menopausal hormone therapy and incidencerisk of breast cancer: systematic review and meta-analysis. Ann Med. 2026Dec;58(1):2640244. doi: 10.1080/07853890.2026.2640244. Epub 2026 Mar.2.     Kaunitz, Wright. Menopausal Estrogen Therapy andRisk of Breast Cancer. Obstet Gynecol. Aug 20263.     Chlebowski RT, Aragaki AK, Pan K, et al.Randomized Trials of Estrogen-Alone and Breast Cancer Incidence: AMeta-Analysis. Breast Cancer Research and Treatment. 2024. 4.     Writing Group for the Women's Health InitiativeInvestigators. (2002). Risks and benefits of estrogen plus progestin in healthypostmenopausal women: Principal results from the Women's Health Initiativerandomized controlled trial. JAMA, 288(3), 321–333.

Today, we are taking a deep dive into an intervention that almost every labor and delivery unit in North America has adopted over the last decade: Quantitative Blood Loss, or QBL. ACOG first recommended quantitative blood loss assessment in Committee Opinion Number 794, published in December 2019. This opinion recommended that every birthing facility implement a standardized, quantitative method for measuring cumulative blood loss at all deliveries, replacing visual estimation as the default approach. This built on earlier ACOG efforts, including the 2015 reVITALize initiative, which standardized obstetric data definitions and defined postpartum hemorrhage using cumulative measured blood loss thresholds (≥1,000 mL regardless of delivery route, or blood loss accompanied by signs/symptoms of hypovolemia). We've all weighed sponges, measured calibrated drapes, and run the math. But here's the million-dollar question: Does measuring blood loss accurately, on its own, actually improve outcomes for patients? The answer is YES….and NO at the same time. Listen in for details as we discuss new data (July 2026 in AJOG) on this topic. 1. White A, Burns RN, Pruszynski JE, Ravindra D, Fin KX, Montgomery T, Jestes E, Ambia AM, Anyaehie B, Duryea EL. Establishing Normal Blood Loss Thresholds at the Time of Delivery Based on Quantitative Blood Loss. Am J Obstet Gynecol. 2026 Jul. DOI: 10.1016/j.ajog.2026.07.028. S0002-9378(26)00395-9. YMOB 16849.2. Quantitative Blood Loss in Obstetric Hemorrhage: ACOG COMMITTEE OPINION, Number 794.Obstetrics and Gynecology. 2019. Committee on Obstetric Practice3. Coomarasamy A, Devall AJ, Bell S, et al. Diagnosis and Treatment of Postpartum Haemorrhage: A Race Against Time. Lancet. 2026.

Learn about Endometriosis - a little-known, but widespread medical condition in women.  Guest: Dr Jagdeep Ubhi | Clinical Professor at Department of Obstetrics and Gynecology, UBC   Host: Jasmeen Kaur

One of the deadliest forms of cancer for women may not start where we once believed. Researchers now know nearly all fatal ovarian cancers begin in the fallopian tubes, not the ovaries. Stephanie Sy discusses with Dr. Rebecca Stone, a professor in the Johns Hopkins Department of Gynecology and Obstetrics, how this understanding is important for patient care. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Fibroids are common but treatment isn't one-size-fits-all. In this podcast, Natalie Friedricks, MD, Medical Director of the Salinas Valley Health Obstetrics and Gynecology clinic, discusses when fibroids need treatment and the benefits of minimally invasive robotic surgery.#Fibroids #WomensHealth #RoboticSurgery #MinimallyInvasiveSurgery #OBGYN #AskTheExperts #SalinasValleyHealth  Learn more about Natalie Friedricks, MD 

Today, I want to tell you a story that sounds like it was completely made up for a movie script, but it's 100% real. Imagine an automotive mechanic in Argentina. He has zero medical training, no background in obstetrics, and no clinical degree. One night, he sees a simple party trick on YouTube: how to get a lost cork out of the inside of an empty wine bottle using nothing more than an inflated plastic bag. Most people would laugh, finish their glass of wine, and move on. But this mechanic, Jorge Odón, looked at that plastic bag and had a radical thought: Could this same basic physics principle be used to safely deliver a trapped baby during second-stage labor? Fast forward through years of engineering refinements, global partnerships, and early clinical pilots, and we get the Odón device- or OdonAssist™. It is, without a doubt, one of the most creative and innovative mechanical concepts to hit the field of operative vaginal delivery in generations. Instead of rigid metal blades applying direct compression, or high-pressure suction cups on the scalp, it uses an inflatable pneumatic cuff wrapped inside a lubricated, double-layered polyethylene sleeve. The inner layer grips the fetal vertex, while the outer layer glides smoothly against the vaginal walls, replacing high friction with plastic-on-plastic sliding action. But, and this is a big "but", as clinicians, we don't practice medicine based on good ideas or clever engineering alone. We practice based on rigorous, reproducible evidence on efficacy and safety. And that's where the narrative gets complicated. Although the device recently secured CE mark approval in Europe, it is not FDA approved in the United States. Why? Because despite nearly two decades of development, it is still facing a major shortage of large-scale Phase 3 comparative data (non-inferiority data). And the data it does have is not quite as impressive as its design would imply. Listen in for details. 1. Mottet N, et al. Safety and efficacy of the OdonAssist inflatable device for assisted vaginal birth: the BESANCON ASSIST study. American Journal of Obstetrics & Gynecology, 2023; 230, S947-S9582. Hotton EJ, Lenguerrand E, Wade J, et al. The OdonAssist inflatable device for assisted vaginal birth—the ASSIST II study (United Kingdom). Am J Obstet Gynecol. 2024;230(3S):S932-S946.e3.3. https://www.mnhi.com/odonassist (CE approval)4. ACOG PB 219; 2020.

Editor's Choice:  Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 updateEditorial: The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS® Gynecologic oncology guidelinesHosted by: Sean C. Dowdy, MD; Division of Gynecologic Oncology, Mayo Clinic College of Medicine, Rochester, MN, USAFeaturing: Gregg Nelson, MD, PhD; Department of Obstetrics & Gynecology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CanadaRichard D. Urman, MD; Department of Anesthesiology, The Ohio State University Wexner Medical Center and College of Medicine, Columbus, OH, USAOlle Ljungqvist, MD, PhD; Department of Molecular Medicine & Surgery, Karolinska Institutet, Stockholm, SwedenCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

In part 2 of this episode of The Phoenix Cast, Violence Prevention Educator Cassandra Carmona-Wayman (she/hers/ella) continues her conversation with reproductive health advocate Cristina Ponce (she/hers) about Abortion Access, Reproductive Coercion, and Survivor Autonomy. Cristina shares her abortion story and shares her lived experiences with these topics. We also unpack how shifting laws, financial barriers, and crisis pregnancy centers impact survivor autonomy and safety. We highlight practical resources like abortion funds, doulas, travel support, and trusted clinic locators. We also break down myths about medication abortion and centering abortion as both healthcare and a crucial safety option for survivors of violence.Content warnings: discussion of abortion (including personal and self-managed abortion stories), reproductive coercion, intimate partner and interpersonal violence, sexual violence (including rape and sexual coercion), pregnancy-related homicide risk, and anti-abortion harassment/misinformation.Additionally:We discuss healthcare clinics and abortion providers near the Denver Metro area. Please be aware of clinics that misrepresent their services and can appear misleading to patients in need of care. Some “crisis pregnancy centers” near campus and in Denver are not medical clinics and may offer misleading or incomplete information about abortion and pregnancy options. When you can, seek licensed providers or clinics that clearly offer full-spectrum reproductive healthcare, and remember you can reach out to the Phoenix Center at Auraria for confidential support and accurate referrals.Sources and Resources mentioned in the episode:American College of Obstetricians and Gynecologists. Committee Opinion No. 554: Reproductive and Sexual Coercion. American College of Obstetricians and Gynecologists, 2013.American College of Obstetricians and Gynecologists. “Reproductive and Sexual Coercion.” ACOG, Feb. 2013,  https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/02/reproductive-and-sexual-coercion.Centers for Disease Control and Prevention. “About Violence and Pregnancy.” Centers for Disease Control and Prevention,  https://www.cdc.gov/intimate-partner-violence/about/violence-and-pregnancy.html.Centers for Disease Control and Prevention. “Pregnancy Resulting from Sexual Violence.” Centers for Disease Control and Prevention,  https://www.cdc.gov/sexual-violence/about/pregnancy-resulting-from-sexualviolence.html.Cobalt Abortion Fund. Cobalt Abortion Fund,  https://cobaltaf.org/.Colorado Doula Project. Colorado Doula Project,  https://www.coloradodoulaproject.org/.Foster, Diana Greene. The Turnaway Study: Ten Years, a Thousand Women, and the Consequences of Having—or Being Denied—an Abortion. Scribner, 2020.Grace, Kelsey T., and Julie C. Anderson. “Reproductive Coercion: A Systematic Review.” Journal of Midwifery & Women's Health, vol. 63, no. 4, 2018, pp. 371–84.Guttmacher Institute. U.S. Abortion Patient and Policy Reports. Guttmacher Institute, https://www.guttmacher.org.Miller, Elizabeth, et al. “Pregnancy Coercion, Intimate Partner Violence and Unintended Pregnancy.” Contraception, vol. 81, no. 4, 2010, pp. 316–22.National Abortion Federation. National Abortion Federation,  https://prochoice.org/.National Academies of Sciences, Engineering, and Medicine. The Safety and Quality of Abortion Care in the United States. National Academies Press, 2018.“North Carolina Bill Would Authorize Deadly Force for Women Seeking Abortions.” WCNC Charlotte,  https://www.wcnc.com/article/news/politics/north-carolina-politics/north-carolina-bill-would-authorize-deadly-force-for-women-seeking-abortions/275-353d54a3-9231-4341-ae44-a127546db76f.Raymond, Elizabeth G., and David A. Grimes. “The Comparative Safety of Legal Induced Abortion and Childbirth in the United States.” Obstetrics & Gynecology, vol. 119, no. 2, 2012, pp. 215–19.“Reproductive Coercion.” The National Domestic Violence Hotline,  https://www.thehotline.org/resources/reproductive-coercion/.“Reproductive Coercion: What Is It?” Teen Vogue,  https://www.teenvogue.com/story/what-is-reproductive-coercion.Sexual Assault Awareness Fund. “Bisexual Women Are More Likely to Have Abortions.” Sexual Assault Awareness Fund, https://saafund.org/bisexual-women-are-more-likely-to-have-abortions/.Society of Family Planning. #WeCount Reports on Abortion Access After Dobbs.Society of Family Planning,  https://societyfp.org/.Tarzia, Laura, et al. “Reproductive Coercion and Abuse: A Systematic Review of Qualitative Evidence.” Trauma, Violence, & Abuse,  https://pmc.ncbi.nlm.nih.gov/articles/PMC5819992/.Van Parys, An-Sofie, et al. “Prevalence and Evolution of Intimate Partner Violence before and during Pregnancy: A Cross-Sectional Study.” BMC Pregnancy and Childbirth, vol. 14, 2014, article 294,  https://doi.org/10.1186/1471-2393-14-294.Washington State Coalition Against Domestic Violence. Pregnancy and Domestic Violence Issue Brief. Washington State Coalition Against Domestic Violence, 2013,  https://wscadv.org/wp-content/uploads/2016/12/pregnancy-dvfr-issue-brief-12-2013.pdf.World Health Organization. Abortion Care Guideline. World Health Organization, 2022.You can learn more about your options with healthcare service providers like Just the Pill. They can provide vital information and assistance with abortion, contraception, and other sexual and reproductive health services. We provide efficient and equitable access to health care by telemedicine. https://justthepill.com/about-us/You can also look into resources like Elevated Access. They are a nonprofit organization that provides free air transportation through a network of volunteer pilots, helping people travel to essential healthcare services they might not otherwise be able to reach. Their services primarily support access to abortion care and gender-affirming care by coordinating safe, confidential flights in partnership with healthcare and advocacy organizations across the United States.Be aware of Denver Metro Crisis Pregnancy Centers (CPCs):The AVI Project https://www.theaviproject.com/Alternatives Pregnancy Center (Alternatives Colorado) https://youhavealternatives.org/Bella Health and Wellness. Bella Health and Wellness.  https://bellahealthandwellness.com/.Alternatives Pregnancy Center. Alternatives Pregnancy Center.  https://youhavealternatives.org/.Marisol Health. Marisol Health.  https://marisolhealth.com/.Life Choices. Life Choices.  https://lifechoices.org/.If you are in crisis and need immediate support, please call our 24/7 interpersonal violence helpline at 303-556-2255.Request an Appointment with an Advocate athttps://www.thepca.org/online-appointment-requestRequest a Violence Prevention Presentation at https://www.thepca.org/prevention-educationInstagram @phoenixauraria

In part 1 of this episode of The Phoenix Cast, Violence Prevention Educator Cassandra Carmona-Wayman (she/hers/ella) talks with reproductive health advocate Cristina Ponce (she/hers) about how abortion care works, common myths about abortion, and the impact of post‑Dobbs restrictions. They also explore reproductive coercion as a form of abuse, its connections to interpersonal violence, and why protecting survivors' bodily autonomy and access to abortion is essential.Content warnings: discussion of intimate partner violence, reproductive coercion, sexual and physical violence, abortion (including later‑term), pregnancy loss, legal and systemic barriers to care, and brief mention of hospitalization due to assault.Additionally:We discuss healthcare clinics and abortion providers near the Denver Metro area. Please be aware of clinics that misrepresent their services and can appear misleading to patients in need of care. Some “crisis pregnancy centers” near campus and in Denver are not medical clinics and may offer misleading or incomplete information about abortion and pregnancy options. When you can, seek licensed providers or clinics that clearly offer full-spectrum reproductive healthcare, and remember you can reach out to the Phoenix Center at Auraria for confidential support and accurate referrals.Sources and Resources mentioned in the episode:American College of Obstetricians and Gynecologists. Committee Opinion No. 554: Reproductive and Sexual Coercion. American College of Obstetricians and Gynecologists, 2013.American College of Obstetricians and Gynecologists. “Reproductive and Sexual Coercion.” ACOG, Feb. 2013,  https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/02/reproductive-and-sexual-coercion.Centers for Disease Control and Prevention. “About Violence and Pregnancy.” Centers for Disease Control and Prevention,  https://www.cdc.gov/intimate-partner-violence/about/violence-and-pregnancy.html.Centers for Disease Control and Prevention. “Pregnancy Resulting from Sexual Violence.” Centers for Disease Control and Prevention,  https://www.cdc.gov/sexual-violence/about/pregnancy-resulting-from-sexualviolence.html.Cobalt Abortion Fund. Cobalt Abortion Fund,  https://cobaltaf.org/.Colorado Doula Project. Colorado Doula Project,  https://www.coloradodoulaproject.org/.Foster, Diana Greene. The Turnaway Study: Ten Years, a Thousand Women, and the Consequences of Having—or Being Denied—an Abortion. Scribner, 2020.Grace, Kelsey T., and Julie C. Anderson. “Reproductive Coercion: A Systematic Review.” Journal of Midwifery & Women's Health, vol. 63, no. 4, 2018, pp. 371–84.Guttmacher Institute. U.S. Abortion Patient and Policy Reports. Guttmacher Institute, https://www.guttmacher.org.Miller, Elizabeth, et al. “Pregnancy Coercion, Intimate Partner Violence and Unintended Pregnancy.” Contraception, vol. 81, no. 4, 2010, pp. 316–22.National Abortion Federation. National Abortion Federation,  https://prochoice.org/.National Academies of Sciences, Engineering, and Medicine. The Safety and Quality of Abortion Care in the United States. National Academies Press, 2018.“North Carolina Bill Would Authorize Deadly Force for Women Seeking Abortions.” WCNC Charlotte,  https://www.wcnc.com/article/news/politics/north-carolina-politics/north-carolina-bill-would-authorize-deadly-force-for-women-seeking-abortions/275-353d54a3-9231-4341-ae44-a127546db76f.Raymond, Elizabeth G., and David A. Grimes. “The Comparative Safety of Legal Induced Abortion and Childbirth in the United States.” Obstetrics & Gynecology, vol. 119, no. 2, 2012, pp. 215–19.“Reproductive Coercion.” The National Domestic Violence Hotline,  https://www.thehotline.org/resources/reproductive-coercion/.“Reproductive Coercion: What Is It?” Teen Vogue,  https://www.teenvogue.com/story/what-is-reproductive-coercion.Sexual Assault Awareness Fund. “Bisexual Women Are More Likely to Have Abortions.” Sexual Assault Awareness Fund, https://saafund.org/bisexual-women-are-more-likely-to-have-abortions/.Society of Family Planning. #WeCount Reports on Abortion Access After Dobbs. Society of Family Planning,  https://societyfp.org/.Tarzia, Laura, et al. “Reproductive Coercion and Abuse: A Systematic Review of Qualitative Evidence.” Trauma, Violence, & Abuse,  https://pmc.ncbi.nlm.nih.gov/articles/PMC5819992/.Van Parys, An-Sofie, et al. “Prevalence and Evolution of Intimate Partner Violence before and during Pregnancy: A Cross-Sectional Study.” BMC Pregnancy and Childbirth, vol. 14, 2014, article 294,  https://doi.org/10.1186/1471-2393-14-294.Washington State Coalition Against Domestic Violence. Pregnancy and Domestic Violence Issue Brief. Washington State Coalition Against Domestic Violence, 2013,  https://wscadv.org/wp-content/uploads/2016/12/pregnancy-dvfr-issue-brief-12-2013.pdf.World Health Organization. Abortion Care Guideline. World Health Organization, 2022.You can learn more about your options with healthcare service providers like Just the Pill. They can provide vital information and assistance with abortion, contraception, and other sexual and reproductive health services. We provide efficient and equitable access to health care by telemedicine. https://justthepill.com/about-us/You can also look into resources like Elevated Access. They are a nonprofit organization that provides free air transportation through a network of volunteer pilots, helping people travel to essential healthcare services they might not otherwise be able to reach. Their services primarily support access to abortion care and gender-affirming care by coordinating safe, confidential flights in partnership with healthcare and advocacy organizations across the United States.Be aware of Denver Metro Crisis Pregnancy Centers (CPCs):The AVI Project https://www.theaviproject.com/Alternatives Pregnancy Center (Alternatives Colorado) https://youhavealternatives.org/Bella Health and Wellness. Bella Health and Wellness.  https://bellahealthandwellness.com/.Alternatives Pregnancy Center. Alternatives Pregnancy Center.  https://youhavealternatives.org/.Marisol Health. Marisol Health.  https://marisolhealth.com/.Life Choices. Life Choices.  https://lifechoices.org/.If you are in crisis and need immediate support, please call our 24/7 interpersonal violence helpline at 303-556-2255.Request an Appointment with an Advocate athttps://www.thepca.org/online-appointment-requestRequest a Violence Prevention Presentation at https://www.thepca.org/prevention-educationInstagram @phoenixauraria

Postpartum psychosis is a rare but serious mental health emergency that can occur after childbirth, causing symptoms like hallucinations, delusions, paranoia, and severe mood changes. Unlike postpartum depression, postpartum psychosis can involve a loss of touch with reality and requires immediate medical attention. The condition is at the center of the Lindsay Clancy trial, which is now underway. Dan spoke with Dr. Nicole Harrington Cirino, a psychiatrist, member of the Perinatal Psychosis Task Force at Postpartum Support International, and Professor of Psychiatry and Behavioral Sciences and Obstetrics & Gynecology at Baylor College of Medicine, who explained the condition, its symptoms, and how it is diagnosed and treated.See omnystudio.com/listener for privacy information.

Editor's Choice:  Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trialEditorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancerHosted by: Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USAFeaturing: Kathleen Moore, MD; Gynecologic Cancer Clinic, Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma City, OK, USARamez N Eskander, MD;  Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, UC San Diego, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

Today, we're diving straight into a topic that hits close to home for millions of patients and providers alike: IUD insertion pain, and more importantly, how we can actually make it better. Now, if you've been practicing or following clinical guidelines for a while, you know the frustrating backstory here. For years, the standard advice was simple: "Just take 800 milligrams of ibuprofen an hour before your appointment." But a 2015 double-blinded, randomized placebo-controlled clinical trial showed that taking a single dose of 800 mg within an hour before insertion did not relieve procedural pain. That was published in the journal Contraception in 2015. This left clinicians wishing for better options. Fast forward to 2024, when the CDC updated its guidelines to formally recommend local analgesia, like lidocaine blocks or topical use, to help manage insertion pain. That was a huge, long-overdue win for patient-centered care. But local numbing isn't the only tool we should be looking at. What if the issue with oral NSAIDs wasn't the medication itself, but how and when we dosed it? That brings us to a brand-new study published in the American Journal of Obstetrics and Gynecology (AJOG), August 2026. Researchers looked at a preemptive, multidose ibuprofen regimen- starting the day before insertion to reach sustained, therapeutic blood levels ahead of time. And the results? They offer some new insights into how we can stack our pain control strategies. So, let's break down what this study found, how it builds on our CDC guidance, and what it means for our clinical practice starting at our next IUD placement. Let's jump in. 1. Bednarek PH, Creinin MD, Reeves MF, et al. Contraception. 2015;91(3):193–197.2. Ouyang C, Lamvu G, Quach H, et al. Multidose Ibuprofen Prior to Intrauterine device insertion (MIPI): a triple blinded randomized controlled trial. American Journal of Obstetrics & Gynecology, August 2026; 235, 330-3373. Management of Premenstrual Disorders: ACOG Clinical Practice Guideline No.7 Obstetrics and Gynecology. 2023. Committee on Clinical Practice Guidelines–Gynecology4. McKenna KA, Fogleman CD. Dysmenorrhea.American Family Physician. 2021.

Podcast family, we pride ourselves on this show on being avant-garde and forward thinking on the topics we choose. For example, on February the 20th, 2026, we released an episode called “New Data: Screen Maternal Ferritin with Prenatal Care?” In that episode we reviewed a publication from the previous month (January 2026) that was released in Lancet Hematology. This study made the case for screening for early iron deficiency, even without anemia, with serum ferritin at the initiation of prenatal care. This was a multicenter, 2-arm, randomized controlled trial. Earlier identification of low serum ferritin prevented iron deficiency anemia in the third trimester. That's a win! Back then, we also stated how Australia has been leading the charge on this with the Australian HOW. That stands for Hematology in Obstetrics and Women's Health. This Australian consensus committee now recommends screening for iron deficiency, not just iron deficiency anemia, at the initiation of prenatal care, at 24 to 28 weeks, and then again at the third trimester when necessary. And now, as of August 2026, we have additional supportive data that including serum ferritin at the initial OB visit is evidence-based and best for the patient! In this episode we will review this brand-new, prospective cohort study published as a Research Letter in the AJOG August 2026.1. Australian HOW: Iron optimisation in pregnancy: a Haematology in Obstetric and Women's Health Collaborative consensus statement; https://onlinelibrary.wiley.com/doi/10.1111/imj.166022. Konecke N, Jackson T, Angeles I. et al. The association between first trimester iron deficiency without anemia and the development of iron-deficiency anemia prior to childbirth. American Journal of Obstetrics & Gynecology, 2026; 235, e36-e383. ACOG Clinical Practice Update: An Update to Clinical Guidance for Delayed Umbilical Cord Clamping After Birth in Preterm Neonates. Obstet Gynecol. 2025 Jul 24;146(3):442-444.

Natalie Crawford, MD is double board certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility and author of the bestselling book, The Fertility Formula. She is co-founder of Fora Fertility, a boutique fertility practice in Austin, Texas and CEO and co-founder of Learn at Pinnacle, a medical education network. Dr. Crawford completed her undergraduate at Auburn University obtaining a degree in Nutrition Science, Medical School at University of Texas Medical Branch, OBGYN Residency at University of Texas Southwestern, and REI Fellowship at University of North Carolina, concurrently obtaining a Master of Science in Clinical Research. Today on the show we discuss how cannabis and alcohol affect fertility in men and women, how long reproductive health may take to recover after quitting, the surprising relationship between GLP 1 medications and fertility, how chronic stress and insulin resistance can make it harder to conceive, the five lifestyle habits that support healthier eggs and sperm, and why proactive fertility testing can help couples avoid losing valuable time. Try Momentous Signature Spec Creatine: https://www.livemomentous.com Use code ADVERSITY for up to 35% off your entire first order Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of The Bleedin' Truth, Dr. Sally McNally sits down to have a conversation with Dr. Jill Hall. Dr. Jill C. Hall is a board-certified Obstetrician/Gynecologist and a fellowship-trained Urogynecologist specializing in Female Pelvic Medicine and Reconstructive Surgery. They cover frequently asked questions including Kegel exercises, stress incontinence, pelvic floor organ prolapse and dysfunction.Dr. Hall received her Bachelor of Science degree in Neuroscience at Brown University. She received her medical degree at the Keck School of Medicine, USC. She completed a residency in obstetrics and gynecology at UCLA and a fellowship in Female Pelvic Medicine and Reconstructive Surgery at Long Beach Memorial Hospital with Dr. Donald Ostergard.Dr. Hall's clinical interests include the evaluation and treatment of urinary and fecal incontinence, pelvic organ prolapse, pelvic pain, and sexual dysfunction. Dr. Hall performs minimally invasive surgeries, including robotic surgeries.Dr. Hall chose to become a Urogynecologist because she believes that being a woman should not have to result in health problems that keep us from living our best lives. She is passionate about educating her patients and treating them with the most up-to-date and evidence-based therapies available. She is a fellow of the American College of Obstetrics and Gynecology and a member of the American Urogynecologic Society."▶ Sally's Childbirth Education & Hypnobirthing Classes: https://drsallymcnally.com/childbirth...▶ Listen to us on Spotify: https://open.spotify.com/show/5awpvBA...▶ Listen to us on Apple Podcasts: https://podcasts.apple.com/us/podcast...

The Bakri Postpartum Balloon was described and first used clinically in 1999 by Dr. Younes N. Bakri (Georgia, USA). It is intended to treat postpartum hemorrhage (PPH). In the United States, it received its first major FDA clearance (via 510(k) for commercial marketing) on April 17, 2002. Manufacturer guidelines for the Bakri (Cook Medical) state that the balloon may be left indwelling for a maximum of 24 hours, but the determination of removal time is left to the clinician once “bleeding is controlled and the patient is stable.” However, the optimal duration of intrauterine balloon tamponade placement remains unclear. One retrospective cohort study from AJOG (Einerson et al) of 274 women found no significant difference in PPH outcomes when intrauterine balloon tamponade was left in place for 2–12 hours, compared with more than 12 hours. However, only 30 women had the intrauterine balloon tamponade placement for 10 hours or less. And remember, this was not a prospective trial looking at a minimum of 2 hours, 2 hours was just the lower margin of the “short duration” group. Now, a new RCT (with authors from Denver and Vermont) published in the July 2026 Green Journal provides new data. In this first of its kind pragmatic, randomized trial of noninferiority, a 6-hour duration of intrauterine balloon tamponade usage for postpartum hemorrhage (PPH) control was compared with an 18-hour duration. Listen in for details. 1. Durfee, J., Adkins, K., Heyborne, K., Larrea, N., & Schultz, C. (2026). Intrauterine Balloon Tamponade Duration for Postpartum Hemorrhage: A Randomized Controlled Trial. Obstetrics & Gynecology, 148(1), 113–120. https://doi.org/10.1097/AOG.00000000000062952. Garabedian C, Prats C, Seco A, Deneux-Tharaux C, Rozenberg P, Berveiller P. Duration of Intrauterine Balloon Tamponade in Post-Partum Haemorrhage Management After Vaginal Delivery: A Secondary Cohort Analysis From the French TUB Trial. BJOG. 2026 Jan;133(1):123-131. doi: 10.1111/1471-0528.18345. Epub 2025 Sep 1. PMID: 40888007; PMCID: PMC12676195.3. Einerson BD, Son M, Schneider P, Fields I, Miller ES. The association between intrauterine balloon tamponade duration and postpartum hemorrhage outcomes. Am J Obstet Gynecol 2017;216:300.e1–5.

INTRODUCING Behind the Knife OBGYN Oral Board Review!The oral boards aren't just about knowledge—they are about executing under pressure. This course is designed to give you the structure and confidence to command the room. We have curated 98 high-yield scenarios covering the "Big Three" of the exam: Obstetrics, Gynecology, and Office Practice. Whether it's a surgical emergency or a complex clinic workup, we will walk you through exactly how to articulate your plan, defend your decisions, and pass this exam.Each scenario includes 2 parts. The first part is a perfectly executed scenario.  If you are able to achieve this level of performance in your preparation you are sure to pass the oral exam with flying colors. The second part introduces high-yield commentary to each scenario. This commentary includes tips and tricks to help you dominate the most challenging scenarios in addition to practical, easy-to-understand teaching that covers the most confusing topics. We are confident you will find this unique, dual format approach a highly effective way to prepare for the test.Please check out the preview episodes below that include Parts A and B, with and without commentary.This course includes access to our Oral Board Simulator.  Step into the hot seat and experience the pressure of the real exam and receive detailed, actionable feedback with the most advanced oral board prep available.   3-Month Purchase - 10 exams 6-Month Purchase - 22 exams 12-Month Purchase - 46 exams Learn More: https://behindtheknife.org/premium/obgyn-oral-board-reviewDOMINATE THE DAY!

How Targeted Therapies Are Reshaping Treatment for Platinum-Resistant Ovarian Cancer Platinum-resistant ovarian cancer remains one of the most challenging settings in oncology, with limited treatment options and historically poor outcomes for many patients. On this episode of Unscripted, the AMCP Podcast, guest host Abby Kim, PharmD, BCOP, Senior Director of Clinical Strategy and Oncology Specialty Solutions at Prime Therapeutics, sits down with Kathleen Moore, MD, Deputy Director of the Fred & Pamela Buffett Cancer Center and Professor of Obstetrics and Gynecology at Nebraska Medicine, to discuss the evolving treatment landscape for recurrent ovarian cancer and the growing role of biomarker-driven care. Dr. Moore explores the history and challenges of treating platinum-resistant disease, reviews the clinical evidence behind ELAHERE®, examines the importance of folate receptor alpha testing, and shares insights on treatment sequencing, patient-reported outcomes, safety and tolerability considerations, and emerging therapies that may further expand options for patients and inform decision-making across managed care. Sponsored by Abbvie, Inc. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Send us Fan MailOBGYN Dr. Richard Myers joins Dr. Erich Schramm to discuss the name change from Polycystic Ovarian Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This syndrome is the combination of three parts: increased polyendocrine hormones (like insulin and androgens), changing metabolism, and differences in ovarian function Dr. Myers explains that the name change to PMOS reflects the changing understanding and focus of the syndrome from a purely ovarian-centered approach to a more holistic, full-body treatment regimen. The doctors also discuss how different patient desires drive different treatment options and the need for individualized, patient-centered care. They finish by looking at new treatments, including GLP-1 and GIP medications that can help address the underlying metabolic components of the PMOS.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In today's episode, we spoke with David O'Malley, MD. Dr O'Malley is a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–James in Columbus, Ohio. In our exclusive interview, Dr O'Malley discussed his approach to treatment selection and sequencing in platinum-resistant ovarian cancer, a disease setting he described as representing the highest unmet need in the field. He emphasized the central role of clinical trial enrollment and biomarker-driven decision-making, alongside practical patient-centered considerations, such as infusion schedule and quality of life.He highlighted the growing importance of antibody-drug conjugates (ADCs) in this setting, noting that folate receptor alpha and HER2 are the two biomarkers most relevant to current practice. Dr O'Malley outlined how National Comprehensive Cancer Network guidelines support treatment across a broader range of expression levels than initial approvals reflected, citing emerging data suggesting activity even at lower expression thresholds. He also addressed payload sequencing, explaining that outside of a clinical trial, he currently uses topoisomerase I–based ADCs and antimicrotubule-based ADCs each one time only, and remains open to targeting the same antigen again if the payload differs.The discussion also touched on combination strategies, resistance biology, and the evolving role of immunotherapy following the survival benefit observed with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-B96 trial (NCT05116189). Dr O'Malley expressed enthusiasm for next-generation payloads, dual-target approaches, and the potential for bispecific antibodies and novel DNA damage response–targeting agents to define the post-ADC treatment landscape.Finally, Dr O'Malley underscored the need for more tumor biopsies to better characterize resistance mechanisms and called for expanded pharmaceutical investment in retreatment and cross-resistance studies to guide future sequencing decisions.

For Dr. Patricia McLelland, becoming a doctor wasn't the plan until a mission trip to Uganda changed everything. In this episode, Tricia shares how being a patient in a third-world hospital shaped the way she practices medicine today, what a mentor taught her about choosing a career based on what she *didn't* enjoy, and how a patient in Portland rewired her entire approach to women's health. Dr. Patricia McLelland is a Specialist in Obstetrics & Gynecology at Galen OB/GYN East. You can read her Substack at https://patriciamclellandmd.substack.com/ or you can connect with her on LinkedIn (https://www.linkedin.com/in/patricia-mclelland-md-3060681b6/).  If you like this episode, we think you'll also like: Dr. Anna George's Morning Cup (E112) Dr. Claudia Kramer's Morning Cup (E115) Dr. Katie Duffy's Morning Cup (E175) Subscribe to the weekly newsletter and be the first to know who upcoming guests are: http://eepurl.com/iGJzII  My Morning Cup is hosted by Mike Costa of Costa Media Advisors and produced by SpeakEasy Productions.

Jill Saberman is a California-based Women's Health Nurse Practitioner. In her professional practices, Jill focuses on Obstetrics & Gynecology, prenatal care, fertility, contraception and menopause. She values helping women understand their bodies, their health, and themselves. In this episode, Jill discusses her philosophy of care which includes these words, “I am forever grateful to be in a partnership with my patients” and focuses on being authentic, being a good listener, and creating a safe space for her patients… professional discretion and compartmentalization… thinking about a career in medicine when she was a child because her father was a physician and her mother is a psychologist and a Biofeedback and Stress Management Practitioner… choosing a different path in college and pursuing art classes and film production classes…graduating with a Bachelor of Arts in Visual Arts with a focus on film, video, and photography… stepping away from the film industry and deciding to consider graduate programs after a conversation with her own OBGYN Nurse Practitioner… pursuing a Masters degree in Nursing Science to become a Women's Health Nurse Practitioner… the winding path that that led her to find her sense of personal empowerment and fulfillment… the importance of sharing our stories and of reminding each other that it is okay to make mistakes while also having a sense of grace for ourselves… and her beautiful closing words, “I would just like for women to be mentors for each other. We all have something that can support, guide, encourage, teach, care, and love for what any individual wants to do or be.”

Think about the last time you had to time something perfectly. Maybe it taking that perfect swing at the baseball, or catching a flight after a commute, or making a high-stakes decision. In the world of high-risk pregnancy, clinicians play a constant game of high-stakes timing with a usual medication called antenatal corticosteroids. Given to moms at risk of giving birth early, these steroids are a gamechanger for a preterm neonate. But there's a catch. If you give them too early, the benefits fade. If you give them too late and she delivers very quickly, they don't have time to work. A brand-new study published in the journal Obstetrics & Gynecology by Mark Clapp et al reveals just how incredibly difficult this balancing act is. This data shows that nearly 26% of pregnant individuals who received these steroids actually went on to deliver completely full-term, exposing babies to medications they might not have needed. So how do we as clinicians solve this OB Goldilocks problem where the stakes are a newborn baby's health? On today's episode, we break down the data behind 'maximizing benefit while avoiding overuse' and what it means for real world practice.Strong Coffee Company - Protein Coffee PLUS MORE; Get 20% OFF | Promo Code: CHAPANOSPINOBG https://promocode.to/strong-coffee-company/chapanospinobg-hbv1. Clapp, Mark A. MD, MPH; Li, Siguo MS; Melamed, Alexander MD, MPH; Reiff, Emily MD; Gyamfi-Bannerman, Cynthia MD, MS; Kaimal, Anjali J. MD, MAS. Maximizing Benefit From Antenatal Steroid Use While Avoiding Overuse. Obstetrics & Gynecology 148(1):p e33-e42, July 20262. FIGO good practice recommendations on the use of prenatal corticosteroids to improve outcomes and minimize harm in babies born preterm. Int J Gynaecol Obstet. 2021 Oct;155(1):26-303. Society for Maternal-Fetal Medicine Special Statement: Quality metrics for optimal timing of antenatal corticosteroid administration; 2022

When Ashley Womble decides she wants to start a family, she worries she'll need to stop taking her antidepressant medication. Instead of finding clear guidance, she runs head-first into a troubling reality: many of the questions pregnant women and their physicians face about medication safety remain difficult to answer because pregnant women have historically been excluded from medical research. This episode looks at the ethical trade offs of leaving pregnant women out of medical research—and what happens when they and their doctors must make high stakes healthcare decisions without high quality evidence.This episode features:Ashley Womble, MPH: Writer and marketing professional.Ruth Faden, PhD, MPH: Philip Franklin Wagley Professor of Biomedical Ethics at the Johns Hopkins Berman Institute of Bioethics.Crystal Clark, MD, MSc: Associate Professor, Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto.Marika Toscano, MD, MS: Assistant Professor of Gynecology and Obstetrics at Johns Hopkins University School of Medicine.This episode contains references to suicide, which may be distressing for some listeners. If you or someone you know is struggling, support is available.In the U.S., you can call or text the Suicide and Crisis Lifeline at 988 or the National Maternal Mental Health Hotline at 1-833-TLC-MAMA.For listeners outside the U.S., the International Association for Suicide Prevention can help connect you with support in your area: www.iasp.info/suicidalthoughts/“playing god?” is a podcast by the iDeas Lab at the Johns Hopkins Berman Institute of Bioethics. To read a transcript of this episode, visit the iDeas Lab website at https://bioethics.jhu.edu/pgs2e6.The Johns Hopkins University Sesquicentennial is proud to support this podcast. JHU celebrates 150 years of pioneering education and research—advancing knowledge to meet the challenges of every generation. Learn more at 150.jhu.edu.

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours NZ listeners - save 10% off Calocurb by using the code Mikkipedia10 at www.calocurb.co.nzIn this episode, Mikki speaks with Hannah Cabre from Pennington Biomedical Research Center about energy expenditure, body composition, ageing, and what really happens to metabolism through midlife and beyond with a focus on sex differences. Hannah's work uses doubly labelled water data, considered the gold standard for measuring total daily energy expenditure in real-world conditions. This allows researchers to understand what people actually burn across the day, beyond estimates from fitness trackers, calorie equations, or short-term lab measures.Mikki and Hannah discuss the idea that metabolism is “stable” from 20 to 60, whether menopause uniquely affects energy expenditure, why body fat can increase even when scale weight stays the same, and why preserving fat-free mass becomes increasingly important with age.This is a nuanced, evidence-based conversation for anyone interested in metabolism, midlife body composition changes, and what ageing really means for energy needs.https://www.pbrc.edu/research-and-faculty/faculty/cabre-hannah.aspxHannah E. Cabré, PhD, RD, is an Assistant Professor at Pennington Biomedical Research Center and Director of the Aging, Gynecology, and Endocrinology Laboratory. Her research focuses on how female sex hormones influence nutrition, health, performance, and body composition across the lifespan, with a particular interest in sex differences during ageing.Hannah's work explores the importance of skeletal muscle maintenance for long-term health, especially during the menopause transition, and how lifestyle interventions may help mitigate age-related changes in body composition and healthspan.  Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwilliden

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-490 Overview: In the US, maternal morbidity and mortality rates are among the highest in the western world, and stroke is one of the leading causes—responsible for 1 of 12 maternal deaths. This rate is estimated to be much higher in high-risk pregnancies. Join us as we discuss a recent study examining rates of maternal stroke in which 1 in 4 women with stroke experienced a missed diagnostic opportunity and hear what these findings mean for your practice. Episode resource links: Haghighi N, Bourscheid RM, Shang C, et al. Identifying missed diagnostic opportunities in maternal stroke. Stroke. 2026;57(2). doi:10.1161/STROKEAHA.125.052995 Chen Y, Shiels MS, Uribe-Leitz T, et al. 2025. Pregnancy-Related Deaths in the US, 2018-2022. JAMA Network Open.  Lappen JR, Pettker CM, Louis JM. 2021. American Journal of Obstetrics and Gynecology. Society for Maternal-Fetal Medicine Consult Series #54: Assessing the Risk of Maternal morbidity and Mortality. American Journal of Obstetrics and Gynecology. Miller EC, Bello NA, Chen PR, et al 2026. Prevention and Treatment of Maternal Stroke in Pregnancy and Postpartum: A Scientific Statement from the American Heart Association. Stroke.  Bushnell C, Kernan WN, Sharrief AZ, et al. 2024. Guideline for the Primary Prevention of Stroke: A Guideline from the American Heart Association/¬American Stroke Association. Stroke.  Guest: Susan Feeney, DNP, FNP-BC, NP-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-490 Overview: In the US, maternal morbidity and mortality rates are among the highest in the western world, and stroke is one of the leading causes—responsible for 1 of 12 maternal deaths. This rate is estimated to be much higher in high-risk pregnancies. Join us as we discuss a recent study examining rates of maternal stroke in which 1 in 4 women with stroke experienced a missed diagnostic opportunity and hear what these findings mean for your practice. Episode resource links: Haghighi N, Bourscheid RM, Shang C, et al. Identifying missed diagnostic opportunities in maternal stroke. Stroke. 2026;57(2). doi:10.1161/STROKEAHA.125.052995 Chen Y, Shiels MS, Uribe-Leitz T, et al. 2025. Pregnancy-Related Deaths in the US, 2018-2022. JAMA Network Open.  Lappen JR, Pettker CM, Louis JM. 2021. American Journal of Obstetrics and Gynecology. Society for Maternal-Fetal Medicine Consult Series #54: Assessing the Risk of Maternal morbidity and Mortality. American Journal of Obstetrics and Gynecology. Miller EC, Bello NA, Chen PR, et al 2026. Prevention and Treatment of Maternal Stroke in Pregnancy and Postpartum: A Scientific Statement from the American Heart Association. Stroke.  Bushnell C, Kernan WN, Sharrief AZ, et al. 2024. Guideline for the Primary Prevention of Stroke: A Guideline from the American Heart Association/¬American Stroke Association. Stroke.  Guest: Susan Feeney, DNP, FNP-BC, NP-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

On today's show, host Dana Pellebon is in conversation with Dr. Mary Fariba Afsari about her new memoir, Labor: One Woman’s Work. Dr. Afsari is a child of Iranian immigrants, a working mother, and the founder of a mobile health clinic, bringing reproductive healthcare to rural patients in the Pacific Northwest. In 2015, Dr. Afsari literally mobilized her practice to meet women where they are. Her clinic on wheels–FemForward Health–travels throughout rural Oregon because too many of these communities lack full-scale OB-GYN services. Dr. Afsari says that people have started driving to find her because they've been recommended by word of mouth. It's a sign of how broken the healthcare system is that a mobile RV clinic is providing better care than industrial medicine to women of color and rural women. Post Dobbs, Dr. Afsari says the fight for reproductive justice is more important than ever.  Dr. Afsari's memoir chronicles her career serving women like her grandmother who died of a pregnancy related complication. She says she wants readers to get a sense of the range of experiences she has from obstetric emergencies to joyous births. They also discuss Dr. Afsari's philosophy of meeting patients with curiosity, how race plays a central role in whether a woman will survive a pregnancy, the lack of gender-affirming care, and the criminalization of OB-GYNs post Dobbs.  Residents of Dane County may be aware of a similar service providing  mobile forensic nurse exams. Mary Fariba Afsari, DO, is a board-certified OB-GYN and the founder of FemForward Health, a mobile women’s health clinic in Portland, Oregon. She completed her medical school at Touro University college of Osteopathic Medicine, her Obstetrics and Gynecology residency at the University of Connecticut School of Medicine and holds an MS in Health Communication from the Tufts University/Emerson College joint program. Dr. Afsari is a passionate advocate for healthcare equity and reproductive justice. She speaks widely on the intersections of medicine, identity, and systemic healthcare reform. Her debut memoir, Labor: One Woman’s Work, was published by Avid Reader Press in April.  Featured image of the cover of Labor: One Woman’s Work. Did you enjoy this story? Your funding makes great, local journalism like this possible. Donate hereThe post One Mobile Clinic Practices Reproductive Justice in Rural Areas appeared first on WORT-FM 89.9.

Podcast Family, in this episode we will focus on the “20-minute rule” for vacuum assisted vaginal delivery. This is an important aspect of neonatal safety and is a vital part of procedure documentation. Documentation for vacuum assisted vaginal delivery should include station at application, number of tractions, number of pop-offs and the total traction time and the vacuum trackable time (time from first application to delivery). This has historical roots as well as new data to validate it (March 2026). Listen in for details. 1. ACOG PB 219; 20202. Preuss E, Porto A, Sheiman V, Bitton M, Tovbin J, Kedem HI, Barzilay E. When to stop? A single center experience on vacuum-assisted deliveries. Eur J Obstet Gynecol Reprod Biol. 2026 Mar 25;320:114983. 3. Teng FY, Sayre JW. Vacuum Extraction: Does Duration Predict Scalp Injury?.Obstetrics and Gynecology. 1997. 4. Tsakiridis I, Giouleka S, Mamopoulos A, et al.Operative Vaginal Delivery: A Review of Four National Guidelines. Journal of Perinatal Medicine. 2020. 16% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG

For most people, donor eggs is at the bottom of the list. It is not where you wanted to land. And if your clinic is recommending it, something in you is saying there has to be more to look at first. Here is what we see every week. The donor egg recommendation rarely arrives after a complete workup. It arrives after looking at the AMH, the FSH, the follicle count, maybe a basic semen analysis, and maybe being told your TSH is normal. Those numbers are real. The diagnosis is real. What gets called complete is the question. This episode is the 11 specific things we most often find skipped before the recommendation gets made. Pull it up. Take notes. Bring it to your next appointment. The 11 patterns: 1. Thyroid, the full panel, not just TSH 2. The gut, including H. pylori 3. Hidden food sensitivities 4. Medications you are already on that affect fertility 5. The vaginal microbiome 6. The seminal microbiome 7. The male partner's full bloodwork 8. Sperm DNA fragmentation 9. Vaginal and seminal cross-contamination between partners 10. The nervous system and HPA axis 11. Liver function and hormone clearance These are the tests that sit outside the standard fertility workup. A 2024 study in Archives of Gynecology and Obstetrics found that ovarian reserve markers like AMH do not significantly predict natural conception in women with regular cycles. The donor egg recommendation comes from one snapshot, not the full investigation. If this is the first episode you have landed on in this series, go back and listen to "Told Donor Eggs Are Your Only Option? Ask This First," then "How Long Should I Try With My Own Eggs Before Donor Eggs?" then "The Gut Findings Your Clinic Did Not Look For," and "Multiple Failed IVF And Told Donor Eggs?" This episode brings all of it together. WHAT YOUR CLINIC MISSED The companion guide walks through all 11 of these patterns in more detail, so you can take it to your next appointment and ask the questions. Email hello@fabfertile.ca, subject line MISSED, and we will send you the guide. FUNCTIONAL FERTILITY SECOND OPINION A free 45-minute call where I review your labs, your history, and your partner's results with you. You leave knowing what your biology has been telling you and what your next decision could be. Email hello@fabfertile.ca, subject line FERTILE, or book here. ABOUT THE HOST I'm Sarah Clark, founder of Fab Fertile and host of Get Pregnant Naturally, a podcast with over one million downloads. My functional fertility team works with couples navigating low AMH and failed IVF, reviewing functional lab results, gut microbiome, food sensitivity, vaginal microbiome, nutrigenomics, HTMA, DUTCH, toxin testing, and bloodwork alongside nervous system work, to help identify patterns that may not have been considered. We work alongside your medical team, not instead of them. Sarah Clark, founder of Fab Fertile, host of Get Pregnant Naturally (1M+ downloads), and author of Fabulously Fertile. If this episode helped, leave a review on Apple Podcasts. It is how other women find this work. TIMESTAMPS 00:00 The Donor Egg Recommendation and What Gets Called Complete 01:00 Who's Reviewing Your Case at Fab Fertile 02:00 Thyroid: The Full Panel, Not Just TSH 03:00 The Gut and H. pylori 04:00 Hidden Food Sensitivities 05:00 Medications That Affect Fertility 06:30 The Vaginal Microbiome 08:00 The Seminal Microbiome 08:30 The Male Partner's Full Bloodwork 09:00 Sperm DNA Fragmentation 09:30 Cross-Contamination Between Partners 11:00 The Nervous System and HPA Axis 11:30 Liver Function and Hormone Clearance 13:00 The Functional Fertility Second Opinion

The March 2026 ACC/AHA Guideline on the Management of Dyslipidemia made a major pivot regarding Lipoprotein(a) by establishing a formal recommendation for universal screening in adults. This 2026 guideline, published in the Journal of the American College of Cardiology, issued a Class 1 recommendation stating that every adult should have their Lp(a) measured at least once in their lifetime. Because Lp(a) levels are genetically determined and remain highly stable throughout a person's life, a single lifetime check is sufficient for the vast majority of the population to establish their baseline risk. Well, that's great for Family medicine or internal medicine, but how does that affect us in women's health? Well, it's complicated: lipoprotein(a) has been associated with an increased risk of VTE and has also been associated, in some studies, with FGR, preeclampsia, and preterm birth! So, can these patients receive oral contraceptives? What about Perioperative and postop care? Do these patients require anticoagulation? What about pregnancy- is LDA recommended here? And lastly, what about TXA use in patients with HMB? This podcast topic comes from one of our podcast family members who is an OBGYN military personnel caring for our wonderful troops overseas. Listen in for details!16% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG1. Ezzat, D., Lopez, D. M., Claggett, B. L., Li, L., Mohammadnia, N., Schuermans, A., Hemeryck, J., Chang, A., Murillo, S., O'Donoghue, M. L., Bikdeli, B., Yu, Z., Natarajan, P., Patel, A. P., Pabon, M. A., & Honigberg, M. C. (2026). Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men. European Heart Journal, ehag252. https://doi.org/10.1093/eurheartj/ehag2522.ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Dyslipidemia Writing Committee. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation, 153, e1155–e1300. https://doi.org/10.1161/CIR.00000000000014233. CDC MEC 4. Prevention of Venous Thromboembolism in Gynecologic Surgery: ACOG Practice Bulletin, Number 232. Obstetrics and Gynecology. 2021. Committee on Practice Bulletins—Gynecology5. Sofi F, Marcucci R, Abbate R, Gensini GF, Prisco D.Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-Analysis of the Literature.Seminars in Thrombosis and Hemostasis. 2017. Dentali F, Gessi V, Marcucci R, et al. Lipoprotein (A) and Venous Thromboembolism in Adults: The American Journal of Medicine. 2007.

In this week's episode, Rex Nelson talks with Dr. Nirvana Manning, head of Obstetrics and Gynecology at UAMS, about maternal health in Arkansas. Manning discusses recent statistics on maternal health in the state and the work needed to improve how Arkansas delivers maternal care. Podcast on Apple, Spotify, and YouTube, or visit arkansasonline.com/podcast23 for an exclusive subscription offer available only to podcast listeners Chapters (00:00:00) - Southern Fried Podcast: Dr. Nirvana Manning(00:01:49) - Physician and Vanderbilt grad on the podcast(00:02:45) - Arkansas maternal health issues(00:08:43) - Arkansas maternal and infant health: Victories and challenges(00:13:36) - Arkansas' problems with rural healthcare(00:17:17) - How do we better educate mothers about pregnancy and maternal health?(00:20:06) - Arkansas Pro-Prenatal Care Program 1(00:24:27) - UAMS Chancellor Dr. Manning at the 2017 Arkansas Healthcare Conference

Hey everyone, thanks for tuning in. If you've spent any time in the OR during a cesarean delivery, you know that the choice between uterine exteriorization and in situ repair usually comes down to how you were trained or personal surgeon preference. It's a debate as old as modern obstetrics. But a major piece of clarity is coming down the pipeline. This episode, we are getting a sneak peek at a brand-new systematic review and meta-analysis dropping this July 2026 in the European Journal of OBGYN. We're asking the big question: is this the study that finally settles the debate once and for all? Grab your coffee, stick around, and let's find out.16% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG​ Coutinho, I. C., Ramos de Amorim, M. M., Katz, L., & Bandeira de Ferraz, Á. A. (2008). Uterine exteriorization compared with in situ repair at cesarean delivery: A randomized controlled trial. Obstetrics & Gynecology, 111(3), 639–647. https://doi.org/10.1097/aog.0b013e31816521e2 . (One of the most heavily cited clinical trials on the subject. It established that women in the exteriorized group experienced a 41% greater risk of moderate-to-severe pain at 6 hours postoperatively compared to the non-exteriorized cohort).​ Tan, H. S., Taylor, R. C., Sharawi, N., Sultana, R., Barton, K. D., & Habib, A. S. (2021). Uterine exteriorization versus in situ repair in Cesarean delivery: A systematic review and meta-analysis. Canadian Journal of Anaesthesia, 69(2), 216–233. https://doi.org/10.1007/s12630-021-02142-8​ Fonseca Queiroz L, Lemos M, Pereira da Silva D . Uterine exteriorization versus in-situ uterine repair during cesarean delivery: a systematic review and meta-analysis of randomized controlled trial. European Journal of Obstetrics and Gynecology and Reproductive Biology, 2026; 323

What happens when a lifelong passion for science, innovation, and helping others comes together in one remarkable career? In this episode of The She Believed She Could™ Podcast, Allison Walsh sits down with Dr. Erica Stockwell, an advanced gynecologic surgeon with AdventHealth for Women, to discuss her groundbreaking work in women's healthcare, minimally invasive surgery, and medical innovation. Dr. Stockwell shares how her background in biomedical engineering, medicine, and business led her to become a pioneer in robotic surgery and surgical technology. From holding medical device patents to helping shape the future of AI-assisted healthcare, she offers a fascinating look at where women's health is headed and why innovation matters more than ever. But beyond her impressive accomplishments, Dr. Stockwell also reveals the deeply personal challenges that shaped her journey. During medical residency, she became a new mother while simultaneously caring for her infant daughter battling cancer. Her powerful story of perseverance, faith, and community support serves as a reminder that even the most successful women face valleys—and that resilience is built by continuing forward through them. Together, Allison and Dr. Stockwell explore leadership, confidence, endometriosis care, women's health advocacy, entrepreneurship, motherhood, and the courage it takes to keep believing in yourself when life gets hard. If you're looking for inspiration, practical wisdom, and a glimpse into the future of healthcare, this conversation is one you won't want to miss. What You'll Learn in This Episode: How innovation is reshaping women's healthcare The benefits of minimally invasive gynecologic surgery Emerging trends in robotic surgery and AI-assisted medicine Why endometriosis requires comprehensive, multidisciplinary care How to build resilience during life's hardest seasons The role of mentorship and support systems in success Why confidence is created through action Lessons on leadership, entrepreneurship, and impact How to navigate motherhood while pursuing ambitious goals The future of women's health technology This episode is sponsored by AdventHealth for Women. Learn more about their Women's Health Navigation Team and how they're making healthcare simpler for women and their families at AdventHealthForWomen.com. Positioned for Partnerships™ Mini Course - Turn your platform into a revenue-generating brand opportunity—without needing a massive following. Learn how to position your brand, create a high-converting media kit, and confidently pitch partnerships so brands instantly understand your value. 

In episode #443 of The Hormone Puzzle Podcast, our guest, Dr. Maribelle Verdiales, talks about Hormonal Changes After 40 and Fertility. More about Dr. Maribelle Verdiales: Dr. Verdiales was born in Puerto Rico, where she completed her medical degree in 2001. She relocated to New York City, where she completed a residency in Obstetrics and Gynecology. Reproductive endocrinology, minimally invasive surgery and pelvic reconstructive procedures became her main points of interest. In 2009, Dr. Verdiales relocated to Georgia with her family to start a private practice. As her practice evolved, she sought a more holistic approach to healthcare for her patients. In 2017 she completed a doctor of naturopathy degree and was able to expand her practice even further by adding new modalities to achieve wellbeing. Today, she is a pioneer in the areas of regenerative and anti-aging medicine. In 2023, she incorporated stem cell and other cell therapies to her toolbox. "The worst question is the one that is not asked", she says frequently. She continues to seek solutions to the challenges faced by her patients, and aims at helping them achieve their maximum potential through a tailored patient specific approach. Thank you for listening! This episode is brought to you in partnership with The Becoming Her Retreat — a transformational experience for women ready to turn their infertility journey into healing, purpose, and impact. Learn more and join the Becoming Her Masterclass at www.fertilitycoachingmastery.com/retreat-masterclass. Follow Dr. Verdiales on Instagram: @‌verdialesmd Follow Dr. Kela on Instagram: @‌kela_healthcoach Get your FREE Fertility Meal Plan: https://hormonepuzzlesociety.com/ Want Dr. Kela to review your case and learn more about working with her and her team, book a telehealth appointment here - https://hormonepuzzlesociety.com/fertility-deep-dive-call/  FTC Affiliate Disclaimer: The disclosure that follows is intended to fully comply with the Federal Trade Commission's policy of the United States that requires to be transparent about any and all affiliate relations the Company may have on this show. You should assume that some of the product mentions and discount codes given are "affiliate links", a link with a special tracking code This means that if you use one of these codes and purchase the item, the Company may receive an affiliate commission. This is a legitimate way to monetize and pay for the operation of the Website, podcast, and operations and the Company gladly reveals its affiliate relationships to you. The price of the item is the same whether it is an affiliate link or not. Regardless, the Company only recommends products or services the Company believes will add value to its users. The Hormone Puzzle Society and Dr. Kela will receive up to 30% affiliate commission depending on the product that is sponsored on the show. For sponsorship opportunities, email HPS Media at media@hormonepuzzlesociety.com

Can a “normal” pelvic exam mask life-altering pain? On this episode of BackTable Women's Health, host Dr. Karen Toubi interviews board-certified OBGYN Dr. Chailee Moss about why common vulvovaginal pain and skin conditions are frequently missed or dismissed as “normal” exams. Dr. Moss explores how gaps between gynecology and dermatology, limited training, and the under-recognition of non-life-threatening but highly morbid pain contribute to these diagnostic challenges, including mental health impact and even suicidality in some cases. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction03:56 - Why Pain Gets Missed08:58 - Building Trust With Time10:51 - Vulvodynia Workup Basics16:02 - Hormonal Vestibulodynia Clues21:21 - New Treatments On Horizon23:07 - Lichen Steroid Maintenance26:25 - Biopsy Decisions And Mimics30:30 - Multimodal Treatment Planning33:00 - Pelvic Floor PT Done Right35:55 - When To Consider Surgery37:33 - Clinical Trials Ketotifen Botox40:40 - Conclusion and Resources --- More about this episode They discuss rebuilding trust through time, attentive listening, and clear communication, along with a detailed evaluation process that includes medication review, targeted symptom questions, Q-tip mapping, vulvoscopy, cultures, and selective biopsy. The approach informs an individualized, multimodal treatment plan. Additional topics include lichen steroid counseling,differentiating mimickers like yeast and irritant dermatitis, and connecting patients to resources such as ISSWSH, ISSVD, and support groups. --- Resources Experiences of Care and Gaslighting in Patients With Vulvovaginal Disorders https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833711 ISSWSH https://www.isswsh.org/ Pudendal Hope https://www.pudendalhope.info/ Tight Lipped https://www.tightlipped.org/ The National Vulvodynia Association https://www.nva.org/ --- BackTable Women's Health is the go-to podcast for gynecologists, gynecologic surgeons, and other healthcare professionals focused on women's health. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

In the ACOG PB 231, Multifetal Gestations Twin Triplet and Higher-Order Multifetal Pregnancies, it states, “based on the improved outcomes reported in singleton gestations, the National Institutes of Health recommends that, unless a contraindication exists, a course of antenatal corticosteroids should be administered to all patients who are at risk of delivery within 7 days and who are between 24 weeks and 34 weeks of gestation, irrespective of the fetal number”. But a BRAND NEW meta-analysis is saying the exact opposite- with a catch. Listen in for details.1. ACOG PB 2312. Felippe, Carolina Alves MS; Ruiz, Sinrraim dos Santos Chaves MD; de Souza, Rebeca Ferreira MS; de Lima, Aliny Silva MS; dos Santos, Priscila Luiza MS; Fonseca, Pandora Eloa Oliveira MS; de Almeida Silva, Ingryd MS; Montes-de-Oca-Saucedo, Carlos Roberto MD; Santana, Ana Cecília Oliveira MS; Veta Darkovski, Jasmina MD; Matlaw, Hadas Rachel MD; Fonseca Queiroz, Laura MD. Antenatal Corticosteroid Use in Twin Pregnancies: A Systematic Review and Meta-analysis. Obstetrics & Gynecology ():10.1097/AOG.0000000000006344, June 4, 2026. | DOI: 10.1097/AOG.000000000000634416% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG

You have done IVF more than once. Maybe twice. Maybe three times. Maybe more. Each cycle they tweaked the protocol. Higher dose. Lower dose. Different stimulation drug. Different trigger. Added growth hormone. Added DHEA. Mini IVF. Dual stim. Each cycle the protocol changed. And now they are telling you donor eggs. Here is the question this episode is about. They changed the protocol every time. Did anyone look at what was already in your body when each of those protocols arrived? That is what this episode is about. The layer underneath every protocol. In this episode: - Protocol vs system: what your clinic was trained to adjust, and what nobody adjusted across any of your cycles - Why the donor egg conversation arrives after the only variable your clinic was trained to address has been exhausted, not after a full review of your body - The thyroid, iron, B12, vitamin D, inflammation, gut, cortisol, mineral, vaginal microbiome, and blood sugar markers that did not change between cycle 1 and cycle 5 - Why we look at ferritin against 80 to 100 going into IVF, not the lab reference of 15 - What a 2024 study in Archives of Gynecology and Obstetrics found about ovarian reserve markers and natural conception — and why donor eggs gets recommended on markers the literature itself does not support If this is the first episode you have landed on in this series, go back and listen to "Told Donor Eggs Are Your Only Option? Ask This First," then "How Long Should I Try With My Own Eggs Before Donor Eggs?" and "The Gut Findings Your Clinic Did Not Look For." This episode builds on all three. ——— WHAT YOUR CLINIC MISSED The full thyroid panel, not just a TSH. The iron panel that flags ferritin against the fertility target. The gut microbiome testing your REI does not order. The inflammatory markers they tell you are normal. And the male side that almost nobody investigates. Email hello@fabfertile.ca, subject line MISSED, and we will send you the guide. ——— FUNCTIONAL FERTILITY SECOND OPINION A free 45-minute call where I review your labs, your history, and your partner's results with you. You leave knowing what your biology has been telling you and what your next decision could be. Email hello@fabfertile.ca, subject line FERTILE, or book here. ——— ABOUT THE HOST I'm Sarah Clark, founder of Fab Fertile and host of Get Pregnant Naturally, a podcast with over one million downloads. My functional fertility team works with couples navigating low AMH and failed IVF, reviewing functional lab results, gut microbiome, food sensitivity, vaginal microbiome, nutrigenomics, HTMA, DUTCH, toxin testing, and bloodwork alongside nervous system work, to help identify patterns that may not have been considered. We work alongside your medical team, not instead of them. Sarah Clark, founder of Fab Fertile, host of Get Pregnant Naturally (1M+ downloads), and author of Fabulously Fertile. ——— If this episode helped, leave a review on Apple Podcasts. It is how other women find this work. ——— TIMESTAMPS 00:00 The Protocol Changed Every Time. Did Anyone Change You? 01:00 Who's Reviewing Your Case at Fab Fertile 02:00 Protocol vs System: The Layer Underneath Every IVF 03:00 What Your Body Brought to Every Cycle 04:30 What the 2024 Research Says About AMH 06:00 The Markers That Did Not Change Between Cycles 07:30 Why Multiple Tests Are Not One Test 09:00 The Donor Egg Recommendation With Half the Data 10:30 The Functional Fertility Second Opinion

Your clinic told you donor eggs. You walked out wondering how much time you actually have left. Whether waiting six months means missing your window. Whether trying with your own eggs one more time is brave or stupid. The honest answer is longer than your clinic implied. And the window is not your AMH number. In this episode: - Why a 2024 study in Archives of Gynecology and Obstetrics found that ovarian reserve markers like AMH do not significantly predict natural conception in women with regular cycles - What the 90-day window before ovulation actually is, and why the eggs you work with six months from now are not the eggs you are working with today - The inputs your clinic's timeline assumed would not change: mitochondrial function, inflammation, iron, B12, zinc, vitamin D, cortisol patterns, toxic load - The clinical pattern we see over more than a decade of cases: month zero to six is where the picture comes into view, twelve to eighteen months is where it can start to move substantially - Why some pictures do not move, and why that is still a reason to look before you decide If this is the first episode you have landed on in this series, go back and listen to "Told Donor Eggs Are Your Only Option? Ask This First" and then "The Gut Findings Your Clinic Did Not Look For." This episode builds on both. ——— WHAT YOUR CLINIC MISSED The full thyroid panel, not just a TSH. The iron panel that flags ferritin. The gut microbiome testing that your REI does not order. The inflammatory markers no one notices. The male side that almost no one investigates. Email hello@fabfertile.ca, subject line MISSED, and we will send you the guide. ——— FUNCTIONAL FERTILITY SECOND OPINION A free 45-minute call where I review your labs, your history, and your partner's results with you. You leave knowing what your biology has been telling you and what your next decision could be. Email hello@fabfertile.ca, subject line FERTILE, or book here. ——— ABOUT THE HOST Now in its eighth year, Get Pregnant Naturally was one of the first podcasts dedicated to the functional fertility approach for low AMH and failed IVF. Hosted by Sarah Clark, founder of Fab Fertile, author of Fabulously Fertile, and host of a podcast with over one million downloads. Fab Fertile is a functional fertility team that works with couples to review the lab work most fertility clinics do not run: gut microbiome, food sensitivity, vaginal microbiome, nutrigenomics, HTMA, DUTCH, full thyroid panel, the iron panel, and inflammation markers, alongside nervous system work. Each week Sarah brings you what the team sees across more than a decade of cases. Sarah Clark, founder of Fab Fertile, host of Get Pregnant Naturally (1M+ downloads), and author of Fabulously Fertile. ——— If this episode helped, leave a review on Apple Podcasts. It is how other women find this work. ——— TIMESTAMPS 00:00 The Donor Egg Recommendation and the Real Question 01:00 Who's Reviewing Your Case at Fab Fertile 01:30 AMH Is Not the Countdown Clock 03:00 The 90-Day Window Before Ovulation 04:30 What Actually Changes In 90 Days 07:00 The Fab Fertile Method: What We Investigate 08:30 Why Some Cases Do Not Shift 09:30 The Functional Fertility Second Opinion

Welcome back, everyone. Today we're diving into one of the most hotly debated topics in obstetrics- should we be treating preeclampsia without severe features with antihypertensive medications during expectant management? Now, if you've been following the literature- and our show, you know that the landmark CHAP trial changed the game for chronic hypertension in pregnancy. It showed us that targeting a blood pressure below 140 over 90 reduces serious maternal complications, without harming the baby. That was a big deal. But here's the thing, CHAP studied chronic hypertension. Then there was the CHIP trial- that also found that tight control of gestational hypertension and nonproteinuric chronic hypertension was also beneficial. These did not address preeclampsia without severe features, and yet, the ripple effects of that trial have sparked a global conversation about whether we should be extending those same treatment principles to women with preeclampsia who don't yet have severe features. And this is where it gets really interesting, because the guidelines don't agree. In the United States, ACOG and the Society for Maternal-Fetal Medicine still say: hold off on antihypertensives unless blood pressures hit the severe range at 160/110. But step outside the US, and you'll find the World Health Organization, the International Society for the Study of Hypertension in Pregnancy, FIGO, NICE, and Hypertension Canada all recommending treatment at 140 over 90, regardless of whether the diagnosis is chronic hypertension, gestational hypertension, or preeclampsia. So who's right? And more importantly what does this mean for the patient sitting in front of you right now, at 34 weeks, with a blood pressure of 150 over 95, some proteinuria, but no severe features? Today, we're going to break this down. We'll review the controversy, walk through the divergent guidelines, and most importantly talk about the real, practical implications that favor treating these patients during expectant management. Because when you're watching someone with preeclampsia, waiting for the right time to deliver, there's a strong argument that controlling their blood pressure isn't just reasonable…may be protective. So grab your coffee, settle in, and let's get into it.1. Society for Maternal-Fetal Medicine Statement: Antihypertensive Therapy For mild chronic Hypertension in Pregnancy-The Chronic Hypertension And Pregnancy Trial. American Journal of Obstetrics and Gynecology. 2022. Society for Maternal-Fetal Medicine; Publications Committee. 2. Preeclampsia. The New England Journal of Medicine. 2022. Magee LA, Nicolaides KH, von Dadelszen P.3. Antihypertensive Drug Therapy for Mild to Moderate Hypertension During Pregnancy.The Cochrane Database of Systematic Reviews. 2018. Abalos E, Duley L, Steyn DW, C.4. Prevention and Treatment of Maternal Stroke in Pregnancy and Postpartum: A Scientific Statement From the American Heart Association. Stroke. 2026. Miller EC, Bello NA, Chen PR, et al.5.Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association. Hypertension. 2022. Garovic VD, Dechend R, Easterling T, et al.

In this re-aired episode, HeHe sits down with Dr. Heather Florescue for an incredibly important and deeply educational conversation about stillbirth prevention, placental health, and the warning signs families deserve to know during pregnancy. Together, they unpack why conversations around stillbirth are so often avoided, how education can empower—not scare—parents, and what proactive care can look like when we truly prioritize maternal and fetal health. Dr. Florescue explains the role of placental function in pregnancy outcomes, why estimated placental volume matters, and how recognizing changes in fetal movement and maternal intuition can be life-saving. She also shares current research, discusses risk factors that are often overlooked, and highlights protocols used in places like the UK and Australia that have helped reduce stillbirth rates through earlier intervention and better patient education. This episode is not about fear. It's about informed awareness, advocacy, and helping families understand that paying attention to your body and your baby matters. If you've ever felt dismissed during pregnancy or wondered whether you were “overreacting” to a concern, this conversation is such an important reminder that your instincts deserve to be heard.   Guest Bio: Dr. Florescue is an ob.gyn. in private practice at Women Gynecology and Childbirth Associates in Rochester, N.Y. She delivers babies at Highland Hospital in Rochester, NY.  She received her medical degree at the University of Rochester School of Medicine & Dentistry, completed her internship and residency in obstetrics & gynecology at the University of Rochester Medical Center.  She is certified by the American Congress of Obstetrics & Gynecology.  She and her husband are parents to a set of triplets.  Dr. Florescue is passionate about the prevention of pregnancy and infant loss and the care for families who suffer these terrible tragedies.  SOCIAL MEDIA: Connect with HeHe on Instagram: https://www.instagram.com/tranquilitybyhehe/  Connect with Dr. Florescue on IG: https://www.instagram.com/drflorescueobgyn/  BIRTH EDUCATION: Learn how to stay in control of your birth and reduce the risk of unnecessary interventions in our Avoid a C-Section Webinar. HeHe breaks down the cascade of interventions, explains what's really happening in the hospital, and shares practical strategies to protect your birth plan, advocate for yourself, and navigate labor with confidence. Perfect for anyone who wants a positive, informed hospital birth experience: https://www.thebirthlounge.com/csection Feeling nervous about speaking up in labor? Our Scripts for Advocacy give you the exact words to handle the most common conversations that can make or break your birth experience. From declining unnecessary interventions to asking the right questions about procedures, these scripts empower you to stay in control, speak confidently, and protect your birth plan — even when the pressure is on. Think of it as your personal toolkit for advocating like a pro, so you can focus on your baby, not the stress: https://www.thebirthlounge.com/Scripts-for-Advocacy And if you haven't grabbed it yet… Snag my free Pitocin Guide to understand the risks, benefits, and red flags your provider may not be telling you about, so you can make informed, powerful decisions in labor: https://www.thebirthlounge.com/pitocin Join The Birth Lounge for judgment-free, evidence-based childbirth education from HeHe that shows you exactly how to navigate hospital policies, avoid unnecessary interventions, and have a trauma-free labor experience, all while feeling wildly supported every step of the way: https://www.thebirthlounge.com/ Want prep delivered straight to your phone? Download The Birth Lounge App for bite-sized birth and postpartum tools you can use anytime, anywhere: https://www.thebirthlounge.com/app   LINKS MENTIONED: Star Legacy Foundation: https://starlegacyfoundation.org/ Count the Kicks: https://countthekicks.org/ PUSH Pregnancy: https://www.pushpregnancy.org/ Tommys.org: https://www.tommys.org/pregnancy-information Saving Babies Lives Care Bundles: https://www.england.nhs.uk/wp-content/uploads/2019/03/Saving-Babies-Lives-Care-Bundle-Version-Two-Updated-Final-Version.pdf

The American College of Obstetricians and Gynecologists (ACOG) does not recommend routine ultrasound measurement of the lower uterine segment (LUS) thickness as part of the evaluation for trial of labor after cesarean delivery (TOLAC). ACOG Practice Bulletin No. 205 (2019) on Vaginal Birth After Cesarean Delivery does not include LUS measurement among its recommendations for TOLAC candidacy assessment. The guideline focuses on clinical factors such as type of prior uterine incision, number of prior cesarean deliveries, and other obstetric history to determine TOLAC candidacy, and emphasizes that most women with one previous low-transverse cesarean delivery should be counseled about and offered TOLAC. But what if you find a likely uterine window at the LUS? Does that mandate a repeat C-section? This topic comes from Serena, one of our podcast family members. Listen in for details. 1. Dr. Chapa's Clinical Pearls, Dec 31., 2023: LUST FOR TOLAC; and follow up episode Jan 15, 20242. ACOG Practice Bulletin No. 205: Vaginal Birth After Cesarean Delivery. Committee on Practice Bulletins—Obstetrics Obstetrics and Gynecology. 2019;133(2):e110-e127. doi:10.1097/AOG.0000000000003078.3. Rozenberg P, Sénat MV, Deruelle P, et al. Evaluation of the Usefulness of Ultrasound Measurement of the Lower Uterine Segment Before Delivery of Women With a Prior Cesarean Delivery: A Randomized Trial. American Journal of Obstetrics and Gynecology. 2022. 4. Swift BE, Shah PS, Farine D. Sonographic Lower Uterine Segment Thickness After Prior Cesarean Section to Predict Uterine Rupture: A Systematic Review and Meta-Analysis. Acta Obstetricia Et Gynecologica Scandinavica. 2019. 5. McLeish SF, Murchison AB, Smith DM, et al. Predicting Uterine Rupture Risk Using Lower Uterine Segment Measurement During Pregnancy With Cesarean History: How Reliable Is It? A Review. Obstetrical & Gynecological Survey. 2023. 6. Jastrow N, Demers S, Chaillet N, et al. Lower Uterine Segment Thickness to Prevent Uterine Rupture and Adverse Perinatal Outcomes: A Multicenter Prospective study.7. American Journal of Obstetrics and Gynecology. 2016. 8. Guerby P, Bujold E, Chaillet N. Impact of Third-Trimester Measurement of Low Uterine Segment Thickness and Estimated Fetal Weight on Perinatal Morbidity in Women With Prior Cesarean Delivery. Journal of Obstetrics and Gynaecology Canada. JOGC. 2022.

OA1264 - Sherise Doyley was in the early stages of labor, in a hospital bed, preparing to deliver her baby, when nurses wheeled in a computer. On the screen was a judge, notifying her of an emergency order by the State of Florida to attempt to force her to undergo a C-section, instead of first attempting vaginal delivery. For 3 hours she advocated for herself, without an attorney, barely covered in a hospital gown. How was any of this legal? What is happening? Jenessa breaks down the history of our rights to make our own medical decisions and how that is legally modified in pregnancy, Lydia shares her own birth experience and how these situations could be handled with actual compassion, and Thomas holds very still in hopes our eyes are based on movement (just kidding, Thomas is very supportive and also outraged). Come rage against the machine with us and hopefully breathe life into a revived pro-choice movement, before it's too late. Amy Yurkanin (Mar. 14, 2026), They Didn't Want to Have C-Sections. A Judge Would Decide How They Gave Birth, ProPublica. Video clips of Doyley hearing, provided by ProPublica's Facebook page Anuli Njoku, Marian Evans, Lillian Nimo-Sefah, & Jonell Bailey (2023). Listen to the Whispers before They Become Screams: Addressing Black Maternal Morbidity and Mortality in the United States, 11 Healthcare 438. Brad N. Greenwood, Rachel R. Hardeman, Laura Huang, & Aaron Sojourner (2020), Physician–patient racial concordance and disparities in birthing mortality for newborns, 117 Proceedings of the National Academy of Sciences 21194. Maternal Mortality Prevention (Dec. 18, 2025). Data from the Pregnancy Mortality Surveillance System, CDC. Bracey Harris & Elizabeth Chuck (Jan. 9, 2026), 'Her worst fear has come to pass': Midwife who advocated for Black women dies after giving birth, NBC News. Camila Domonoske (Apr. 17, 2018), 'Father Of Gynecology,' Who Experimented On Slaves, No Longer On Pedestal In NYC, NPR. Megan L. Swanson, Sara Whetstone, Tushani Illangasekare, & Amy (Meg) Autry (2021), Obstetrics and Gynecology and Reparations: The Debt We Owe (and Continue to Accumulate), 5 Health Equity 353. Nicole Loy (May 16, 2025), Pain and Gynecology: Raising Standards of Care, The Healthcare Review at Cornell University. Jess Mador (July 29, 2025), A Brain-Dead Pregnant Woman Was Kept Alive in Georgia. It's Unclear if State Law Required It, KFF Health News. (June 2025), Pregnancy Exceptionalism: A Review of Restrictions on Advance Directives, Pregnancy Justice. U.S. Const. amend. IX Jacobson v. Massachusetts, 197 U.S. 11 (1905) Rochin v. California, 342 U.S. 165 (1952) Cruzan v. Director, Missouri Dep't of Health, 497 U.S. 261 (1990) Washington v. Harper, 494 U.S. 210 (1990) Roe v. Wade, 410 U.S. 113 (1973) Planned Parenthood of Southeastern Pa. v. Casey, 505 U.S. 833 (1992) Dobbs v. Jackson Women's Health Organization, 597 U.S. 215 (2022) Heller v. Doe, 509 U.S. 312 (1993) State Dept. of Human Services v. Northern, 563 S.W.2d 197 (1978) Lane v. Candura, 6 Mass. App. Ct. 377 (1978) Koskenoja v. Whitmer, Mich. Ct. Cl. (2026) (Apr. 20, 2026), Michigan Pregnancy Exclusion Law is Unconstitutional, Compassion & Choices. Check out the OA Linktree for all the places to go and things to do!  

Outside of pregnancy, guidelines emphasize diabetes self-management education and support to facilitate informed decision making, self-care behaviors, problem solving, and active collaboration with health care professionals. This includes, in those with good health literacy, the concept of patient-led self-titration of basal insulin results which has data that it improves glycemic management compared with clinician-led titration for type 2 diabetes among nonpregnant adults. But what about for GDM? Can patient's self manage their BASAL insulin? In this episode, we will review a new RCT published in April 2026 in the Green Journal on this very subject. As novel as this is, it is not the first to report on this as it was also published (retrospective study in the UK) in 2022. This is a novel approach to insulin in GDM but there are some questions that remain. Listen in for details.1. Boonpattharatthiti K, Wechkunanukul K, Mayang N, et al . Comparison of Insulin Titration Strategies for Glycemic Control in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.Diabetes Care. 2025. 2. Valent, Amy M. DO, MCR; Barbour, Linda A. MD, MSPH. Insulin Management for Gestational and Type 2 Diabetes in Pregnancy. Obstetrics & Gynecology 144(5):p 633-647, November 2024. | DOI: 10.1097/AOG.00000000000056403. Wang, Xiao-Yu MD; Gabbe, Steven MD; Landon, Mark B. MD; Venkatesh, Kartik K. MD, PhD et al. Patient-Led Insulin Titration for Glycemic Management With Gestational Diabetes Mellitus: A Randomized Controlled Trial. Obstetrics & Gynecology 147(4):p 501-509, April 2026. 4. McGovern AP, Hirwa KD, Wong AK, et al. Patient-led rapid titration of basal insulin in gestational diabetes is associated with improved glycaemic control and lower birthweight. Diabet Med. 2022;39:e14926. doi: 10.1111/dme.14926

Hyperemesis gravidarum (HG) represents the most severe end of the nausea and vomiting of pregnancy spectrum. It has a reported incidence of approximately 0.3–3% of pregnancies and is the most common cause of hospitalization in early pregnancy and the second most common cause of hospitalization in pregnancy overall. In June 2024, the ACOG published a Clinical Expert series summarizing the inpatient management of HG. In that guidance, it describes mirtazapine as an “alternative pharmacologic” option. How effective is this medication compared to ondansetron? A new study (published ahead of print on 12/30/25 and officially out June 2026), out of Denmark, sheds some new light on this medication. This trial is the first double-blind RCT comparing mirtazapine to ondansetron AND placebo. Although a BIG limitation of this study exists (which we will discuss), it does provide some interesting insights. Listen in for details.1. (ACOG CES) Clark, Shannon M. MD; Zhang, Xue MD; Goncharov, Daphne Arena MD. Inpatient Management of Hyperemesis Gravidarum. Obstetrics & Gynecology 143(6):p 745-758, June 2024. | DOI: 10.1097/AOG.00000000000055182. Ostenfeld, AnneDroogh, Marjoes et al.Mirtazapine or ondansetron for hyperemesis gravidarum. A randomized placebo-controlled trial. American Journal of Obstetrics & Gynecology, June 2026

When Kemi Doll was in medical school, she learned that Black women are twice as likely to die from uterine cancer as white women, and also suffer disproportionately from other uterine-related conditions. What wasn't explained was why. Now a gynecologic oncologist, Doll has made it her mission to change these trends and improve care for Black women.  She joins Flora to discuss her new book, “A Terrible Strength: The Hidden Crisis of the Black Womb and Your Survival Guide to Healing.” They explore the way systemic racism and the normalization of Black women's pain lead to later diagnoses of uterine cancer and poorer health outcomes for a range of gynecologic conditions including fibroids, endometriosis, and heavy periods. And Doll explains the problem with using reproductive health as a synonym for uterine health.  Guest:  Dr. Kemi Doll is a gynecologic oncologist and professor at the University of Washington Schools of Medicine and Public Health.  Other episodes you may enjoy: Endometriosis Is Common. Why Is Getting Diagnosed So Hard? A Black Physician's Analysis Of The Legacy Of Racism In Medicine Want SciFri gear? Check out our new shop! Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-4-SCIFRI